There has been much media attention in the past few years to the condition dubbed ‘flesh-eating disease’, which refers, primarily, to a form of invasive group A beta hemolytic streptococcal (GABHS) infection that leads to fascia and muscle necrosis. In 1999, the Canadian Paediatric Society issued a statement on the state of knowledge and management of children, and close contacts of persons with all-invasive GABHS disease (1). The present note is intended to deal specifically with necrotizing fasciitis (NF) by providing an update on the limited current state of knowledge, diagnosis and management. Surveillance to establish actual national rates and epidemiology of NF through the Canadian Paediatric Society is proposed.

**DEFINITIONS AND EPIDEMIOLOGY**

NF is a deep-seated infection of the subcutaneous tissue that results in the progressive destruction of fascia and fat (2). It is a rare illness that causes extensive tissue destruction and can lead to death. There are many causes of NF, including GABHS, *Clostridium perfringens*, *Clostridium septicum*, *Vibrio* species and fungi of the Mucorales family. In general, NF is classified into two types. Type I NF refers to mixed infections involving anaerobes (most commonly *Bacteroides* and *Peptostreptococcus* species), and one or more facultative anaerobes, such as streptococci (non-GABHS) and members of the Enterobacteriaceae family (eg, *Escherichia coli*, and *Enterobacter*, *Klebsiella* and *Proteus* species) (3). Type II NF refers to infections that are caused by invasive GABHS. The most common type of NF is type II, which is the focus of the bulk of this note.

Invasive GABHS disease is defined by the isolation of group A streptococcus from a normally sterile site such as blood, cerebrospinal fluid or pleural fluid (4). GABHS-related NF either may occur as a part of streptococcal toxic shock syndrome (STSS), or may occur in patients with no signs of shock or organ failure. STSS is defined as the isolation of group A streptococcus from a normally sterile site in association with hypotension and multisystem organ failure (Table 1) (5). In Canada, it is estimated that 90 to 200 cases of NF occur each year in all age groups (6), but annual national estimates in children are, largely, unknown. Although there are many case reports and case series of NF, limited popula-

**TABLE 1**

**Case definition for streptococcal toxic shock syndrome**

| Isolation of group A streptococcus (*Streptococcus pyogenes*) from a normally sterile site (eg, blood, cerebrospinal fluid, pleural fluid)* and |
| Hypotension (less than fifth percentile of systolic blood pressure for children or less than 90 mmHg for adolescents) and two or more of: |
| 1. Renal impairment (creatinine greater than two times the upper limit for age) |
| 2. Coagulopathy (platelets less than 100,000 x 10⁶ U/L or evidence of disseminated intravascular coagulopathy) |
| 3. Liver involvement (alanine aminotransferase, aspartate aminotransferase or bilirubin greater than two times the upper limit of normal) |
| 4. Adult respiratory distress syndrome (pulmonary infiltrates and hypoxemia without heart failure or generalized edema) |
| 5. Generalized erythematous rash that may desquamate |
| 6. Soft tissue necrosis in the form of necrotizing fascitis, myositis or gangrene |

*If group A streptococcus is isolated from a nonsterile site (eg, throat, sputum, vagina) but the patient has hypotension and two of criteria 1 to 6 above, it is considered a probable case if no other etiology for the illness is found*

---

**Correspondence and reprints:** Dr H Dele Davies, Child Health Research Unit, Alberta Children's Hospital, 1820 Richmond Road SW, Calgary, Alberta T2T 5C7. Telephone 403-229-7815, fax 403-541-7508, e-mail dele.davies@crha-health.ab.ca

---

*Can J Infect Dis Vol 12 No 3 May/June 2001*
tion-based studies that involve children primarily have been published. In a large population-based study performed in Ontario from 1992 to 1996 (7), 10 children had NF with an incidence of 0.08/100,000 children/year and accounted for 4% of all invasive cases. About 50% of GABHS-related NF cases are associated with STSS (7). The incidence of both type I and type II NF in the rest of Canada is unknown.

CLINICAL PRESENTATION

Type I NF typically involves the abdominal wall, perianal and groin areas, and postoperative wounds (5,8,9). In newborns, type I NF may be a serious and life-threatening complication of omphalitis (8,10). Erythema and edema around the umbilicus can progress within hours or days, leading to a purplish discoloration and periumbilical necrosis. Anterior abdominal wall involvement often extends to involve the flanks and chest wall. In a retrospective study involving 11 newborn infants with periumbilical NF over a 20-year period, a total of 38 bacterial isolates was recovered involving 21 aerobic and facultative, and 17 anaerobic bacteria. Aerobic or facultative bacteria only were present in one patient, anaerobes only in two (18%), and mixed aerobic and anaerobic flora in eight (73%). Multiple organisms were recovered from all patients, and the number of isolates varied from two to six (average 3.5 isolates/specimen). The predominant isolates were Peptostreptococcus species (seven isolates); Bacteroides fragilis group (six isolates); streptococcus group B (four isolates); and Streptococcus aureus, streptococcus group D, E coli and Proteus mirabilis (three isolates each). All patients underwent extensive debridement and resection, and received supportive and antimicrobial therapy. Six (55%) of the patients died.

Type II NF has initial nonspecific clinical findings. The lack of a rash or confusion with cellulitis when a rash is present makes the early diagnosis of this form of NF difficult (11,12). Early on, NF mostly involves the subcutaneous tissue, with normal overlying skin. Excruciating pain that is out of keeping with the clinical findings is an important clue to the diagnosis (11), and relatively high temperatures are common (12). Local evidence of an abrasion, cut or contusion at a body site are other common findings on presentation (reflecting the entry point of the GABHS). When associated with STSS, hypotension can develop within 24 h or as late as four weeks after the precipitating event. Fever and ‘influenza-like’ symptoms, such as myalgia and chills, are prominent symptoms and, often, are evident at presentation. Clues to differentiating the syndrome from influenza may include the absence of respiratory symptoms or a lack of history of close contacts with influenza-like illness, the presence of focal pain rather than generalized myalgia, and a history of recent penetrating or blunt trauma in up to 40% of patients (7). GABHS-related NF in children is most likely to occur on the lower extremities, including the thigh and groin (7). Overall, 16% of all invasive GABHS infections in children are associated with a chronic underlying illness (7), persons with leukemia having an increased risk.

ASSOCIATION WITH VARICELLA

Varicella infection has been identified often in case series and in population-based studies as a major risk factor for invasive GABHS infections among children (4,7,15-21). Children younger than 10 years of age with chickenpox have a 58-fold increase in the risk of developing invasive GABHS disease during the two weeks after the onset of skin lesions (7). Between 6% and 37% of invasive group A streptococcal infections in children are associated with varicella (4,7,16). Reports of outbreaks of invasive group A streptococcal infection and varicella in southern California (22) and Seattle (14) suggest that outbreaks may occur with the simultaneous presence of high rates of varicella, and the circulation of a virulent group A streptococcal clone in the community. Varicella may allow invasion via another less apparent portal, such as lesions in the mouth or the respiratory tract, as well as via skin lesions.

Invasive GABHS infections (most commonly cellulitis and occasionally NF) that occur as complications of varicella generally manifest four to six days after the onset of rash (7). Initially, the signs may be nonspecific, and the signs of infected pox lesions may be absent. Secondary fever (fever occurring after the resolution of initial chickenpox fever) is common (11). As noted above, a key feature of NF may be severe, localized pain that is out of proportion with the appearance of a lesion. In a case control study that was performed in Los Angeles and Orange counties (23), when children with varicella who developed invasive GABHS disease were compared with control children who had uncomplicated varicella, the former were more likely to be cared for in the home rather than at out-of-home child care; to report having asthma; to be taking albuterol; to be a secondary varicella case within a household; to report fever after day 2 of varicella; and to have contacted a health care provider later than controls (day 3.8 rather than day 1.7, P<0.001). However, identification of these potential risk factors may not help clinicians trying to identify which child with prolonged or secondary fever may have a GABHS infection such as NF. In a Canadian study, persons with asthma were not identified to be at greater risk of invasive GABHS (7). A high index of suspicion, the occurrence of severe focal pain, documented contact with GABHS at school, home or in the hospital, and knowledge of whether other cases have occurred in the community recently may be of more help in making a diagnosis. Cases complicating chickenpox and other cases in children do not differ in the proportion of children with underlying illness or in case fatality (7). Other types of skin lesions, including eczema, also appear to increase the risk of invasive disease, presumably because they provide a focus of entry for the bacteria (11).

LABORATORY FINDINGS

The laboratory features of severe, invasive GABHS disease are nonspecific (Tables 1 and 2). The association of a normal or elevated white blood cell count with a left shift, in association with severe pain, may be the only early clue to the diagnosis of NF. An elevated creatine kinase level should alert the
TABLE 2

Early diagnostic clues for severe invasive group A streptococcal infections

<table>
<thead>
<tr>
<th>Clinical</th>
<th>Laboratory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza-like symptoms such as fever, aches, pains and chills</td>
<td>Normal or elevated white blood cell count, with marked ‘left shift’ (high number of immature neutrophils)</td>
</tr>
<tr>
<td>Severe pain</td>
<td>Prolonged prothrombin time and partial prothrombin time</td>
</tr>
<tr>
<td>Rapid breathing, signs of pleural effusion</td>
<td>High creatinine phosphokinase (CPK)†</td>
</tr>
<tr>
<td>Secondary fever following varicella infection suggests invasive group A streptococcal disease</td>
<td>Magnetic resonance imaging (or computed tomography scan or ultrasound if magnetic resonance imaging is not available)</td>
</tr>
<tr>
<td></td>
<td>This should not delay surgical consultation</td>
</tr>
</tbody>
</table>

*None of the signs and laboratory features are specific, and all the features noted in Table 1 can occur at any time. †CPK elevation may be a sign of early necrotizing fasciitis with muscle involvement (myositis), but fasciitis may still occur in the presence of a normal CPK if there is no muscle involvement.

There is also evidence from case reports and one stratified case control study that intravenous immunoglobulin may be life-saving for patients meeting the case definition for STSS (27). A single dose of 2 g/kg/day or doses of 400 mg/kg for up to five days have been used, but the most efficacious dosing and frequency of administration have not been determined.

CHEMOPROPHYLAXIS OF CONTACTS OF PERSONS WITH GABHS-RELATED NF

At a rate of 2.9/1000 population, the risk of secondary related invasive GABHS disease (including NF) in household members of patients with invasive GABHS disease is almost 200 times that of the general population (4). Other authors have noted clusters of severe GABHS infection (28). This increased risk of disease among close contacts, and the high rates and severity of sequelae of NF have led most public health authorities in Canada to recommend that close household contacts (persons spending more than 4 h/day or 20 h/week together, sharing sleeping arrangements or having direct mucous membrane contact within seven days of illness of the index patient) of persons with severe group A streptococcal infections should receive chemoprophylaxis. Most authorities in Canada recommend prophylaxis with drugs such as penicillin, first-generation cephalosporins, clindamycin or erythromycin for 10 days. However, definitive studies of the benefit of chemoprophylaxis have not been conducted, and other jurisdictions suggest making decisions on a case by case basis (29). Rifampin, the usual chemotherapeutic agent for meningococcemia and *Haemophilus influenzae* disease, is poor at eradicating group A streptococcal carriage and is, thus, not recommended in the setting of GABHS-related NF disease (30).

NONSTEROIDAL DRUGS AND TYPE II NF

Some investigators have hypothesized that nonsteroidal anti-inflammatory drugs (NSAIDs) increase the risk of GABHS NF, particularly among children with varicella (14,31-33). This hypothesis has some biological plausibility because NSAIDs impair granulocyte function, including chemotaxis, phagocytosis and bactericidal activity (32). However, there have been no well controlled studies to deny or confirm such an association. One case control study (17) found that NSAID use was significantly more common among varicella and NF cases than among controls. However, in more than three-
quarters of the cases, the NSAID use occurred following the onset of symptoms of secondary infection. This suggests an ‘indication bias’ and may be due to NSAIDs being given as a response to infection in persons with severe disease rather than a cause of the severity of the illness. The need to define clearly the temporal relationship between NSAID exposure and NF needs to be addressed in future studies evaluating a potential association. One study involving an NSAID and NF model in rabbits suggested that the apparently greater severity of NF in humans treated with an NSAID may be due to the therapeutic delay induced by the misleading clinical effects of the NSAID and not to inhibition of antibacterial defence (34).

ADJUNCTIVE THERAPY

NF and other severe GABHS infections may be associated with an absence of neutralizing antibody, and providing such antibody in normal immunoglobulin may be of value. There is level 2 and level 3 evidence from case reports and one stratified case control study that intravenous immunoglobulin may be life-saving in patients meeting the case definition for STSS (27,35,36). Doses of up to 2 g/kg/day for one to five days have been used and have been shown to increase superantigen-neutralizing activity (27,35). Hyperbaric oxygen (HBO) has been reported in case reports and case series (25,37,38) to be useful as adjunctive therapy of Type 1 NF but no controlled studies exist and its role in GABHS fasciitis is unknown. Two of 12 patients receiving as many as 12 HBO treatments for GABHS NF (14) in one study developed complications, including an inadvertent extubation during transport from the chamber and an episode of severe bronchospasm. The use of HBO for the management of any type of NF should be considered to be experimental.

CONCLUSION

NF is a relatively rare but life- or organ-threatening condition that is a medical emergency. Type 1 NF is less common due to mixed bacteria and, often, is associated with intra-abdominal infections or complications of surgery. Type II NF is due to GABHS. Both types require immediate surgical and medical intervention. The actual population-based rates of these diseases in Canada and their outcomes are areas in need of research.

REFERENCES


INFECTION DISEASES AND IMMUNIZATION COMMITTEE

Members: Drs Upton Allen, The Hospital for Sick Children, Toronto, Ontario; H Dele Davies, Division of Infectious Diseases, Alberta Children's Hospital, Calgary, Alberta; Gilles Delage, Epidemiology and Microbiology, Hema-Quebec, Saint-Laurent, Quebec (chair, 1996-2000); Joanne Embree, The University of Manitoba, Winnipeg, Manitoba (chair); Mireille Lemay, Department of Infectious Diseases, Sainte-Justine Hospital, Montreal, Quebec; Charles Morin, Complexe hospitalier Sagamie, Chicoutimi, Quebec (director responsible, 1997-2000); Gary Pekeles, The Montreal Children's Hospital, Montreal, Quebec (director responsible); Ben Tan, Division of Infectious Diseases, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan (1994-2000)
Consultants: Drs Noni MacDonald, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia; Victor Marchessault, Cumberland, Ontario
Liaisons: Drs Scott Halperin, Department of Pediatrics, IWK-Grace Health Centre, Halifax, Nova Scotia (IMPACT); Susan King, Division of Infectious Diseases, The Hospital for Sick Children, Toronto, Ontario (Canadian Paediatric AIDS Research Group); Monique Landry, Direction de la santé publique de Laval, Laval, Quebec (Public Health); Larry Pickering, Centre for Pediatric Research, Norfolk, Virginia (American Academy of Pediatrics); John Waters, Alberta Health, Edmonton, Alberta (Epidemiology)
Principal author: Dr H Dele Davies, Division of Infectious Diseases, Alberta Children's Hospital, Calgary, Alberta

The recommendations in this statement do not indicate an exclusive course of treatment or procedure to be followed. Variations, taking into account individual circumstances, may be appropriate.

Internet addresses are current at the time of publication.
This article also appears in Paediatr Child Health 2001;6(5):243-247.